We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ALTME market cap is 4.43M. The company's latest EPS is EUR -0.2367 and P/E is -0.68.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 279k | 147k | 82k | 34k | 17k |
| Operating Income | -3.94M | -5.75M | -13.45M | -12M | -5.62M |
| Net Income | -861k | -10.41M | -14.45M | -15.13M | -6.74M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 1.73M | 10.65M | 9.77M | 5.24M | 2.49M |
| Total Liabilities | 3.59M | 2.96M | 5.27M | 6.51M | 2.79M |
| Total Equity | -1.85M | 7.7M | 4.5M | -1.27M | -294k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -4.29M | -5.22M | -12.38M | -12.14M | -5.64M |
| Investing | -16k | -39k | -14k | -21k | -19k |
| Financing | 1.4M | 14.18M | 11.5M | 7.29M | 3.27M |
| Market Cap | 4.43M |
| Price to Earnings Ratio | -0.68 |
| Price to Sales Ratio | 266.67 |
| Price to Cash Ratio | 2.03 |
| Price to Book Ratio | -15.48 |
| Dividend Yield | - |
| Shares Outstanding | 28.45M |
| Average Volume (1 week) | 511.73k |
| Average Volume (1 Month) | 405.96k |
| 52 Week Change | -88.84% |
| 52 Week High | 1.90 |
| 52 Week Low | 0.1272 |
| Spread (Intraday) | 0.01 (3.32%) |
| Company Name | Noxxon Pharma NV |
| Address |
max-dohrn-strasse 8-10 berlin 10589 |
| Website | https://www.tmepharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
